Abstract Body

Cryptococcus is a leading cause of death among people living with HIV. Clinic-based rapid testing may expedite prophylaxis to prevent meningitis and mortality. The objective of this analysis was to determine the diagnostic accuracy of a cryptococcal antigen (CrAg) lateral flow assay (LFA) when tested at the clinical point-of-care among HIV+ individuals with low CD4 count.

We screened non-pregnant adults 18+ years of age seeking voluntary HIV testing at iThembalabantu clinic in Umlazi Township, South Africa from November 2017 to February 2019. Participants testing HIV+ and consenting to participate were enrolled, completed a demographic survey and clinical assessment, and received a clinic-based rapid CD4 test. Among those with CD4 count ?200 cells/mm[sup]3[/sup], a trained nurse conducted clinic-based CrAg LFA screening (Immy Diagnostics, Norman, USA) and collected a blood sample for gold-standard laboratory-based enzyme immunoassay (EIA) CrAg testing at the BARC lab (Johannesburg, South Africa). Diagnostic performance was assessed by calculating sensitivity, specificity, and positive and negative predicative values compared to gold-standard serum CrAg EIA.

Among 1,493 eligible participants screened, 720 (48.2%) tested HIV+ and received rapid CD4 testing. Of the 164 participants with CD4 count ?200 cells/mm3, all received clinic-based CrAg LFA testing and 162 had gold-standard CrAg EIA testing. CrAg prevalence was 6.1% by serum CrAg LFA and 4.9% by serum CrAg EIA. Serum CrAg LFA testing correctly identified seven of eight CrAg positives by EIA (87.5%, 95% confidence interval [CI]: 50.8-99.9%); specificity was 98.1% (CI: 94.2-99.6%) with three false positives and one false negative. The positive predictive value was 70.0% (CI: 39.2-89.7%) and negative predictive value was 99.3% (CI: 96.0-100.0%) (Table). Diagnostic performance was similar among participants with a CD4 count <100 cells/mm3.

Serum CrAg LFA delivered at the point-of-care showed high diagnostic accuracy compared to the gold-standard CrAg EIA, though with a lower positive predictive value suggesting the need for confirmatory testing. These results indicate that serum CrAg LFA may be feasible and accurate to perform at the clinical point-of-care to more rapidly identify HIV+ patients with cryptococcal antigenemia and intervene to prevent meningitis and mortality.